Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Adipose-derived cellular therapies in solid organ and vascularized-composite allotransplantation.

Stivers KB., Beare JE., Chilton PM., Williams SK., Kaufman CL., Hoying JB.

Narrative Review on Chronic Wound, Immune Modulation, published in Curr Opin Organ Transplant (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Opin Organ Transplant (2017)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
28873074
DOI
10.1097/MOT.0000000000000452
Citations
12

Abstract (original English)

Purpose of review Controlling acute allograft rejection following vascularized composite allotransplantation requires strict adherence to courses of systemic immunosuppression. Discovering new methods to modulate the alloreactive immune response is essential for widespread application of vascularized composite allotransplantation. Here, we discuss how adipose-derived cellular therapies represent novel treatment options for immune modulation and tolerance induction in vascularized composite allotransplantation. Recent findings Adipose-derived mesenchymal stromal cells are cultured from autologous or allogeneic adipose tissue and possess immunomodulatory qualities capable of prolonging allograft survival in animal models of vascularized composite allotransplantation. Similar immunosuppressive and immunomodulatory effects have been observed with noncultured adipose stromal-vascular-fraction-derived therapies, albeit publication of in-vivo stromal vascular fraction cell modulation in transplantation models is lacking. However, both stromal vascular fraction and adipose derived mesenchymal stem cell therapies have the potential to effectively modulate acute allograft rejection via recruitment and induction of regulatory immune cells. Summary To date, most reports focus on adipose derived mesenchymal stem cells for immune modulation in transplantation despite their phenotypic plastic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsGraft SurvivalHumansImmunosuppression TherapyRatsRats, Inbred LewSwineVascularized Composite Allotransplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research